Drug Profile
CV 9104
Alternative Names: CV-9104; RNActive®-derived prostate cancer vaccineLatest Information Update: 14 Aug 2019
Price :
$50
*
At a glance
- Originator CureVac
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 14 Aug 2019 Discontinued - Phase-II for Prostate cancer (First-line therapy) in Germany (Intradermal)
- 08 Sep 2017 Safety and efficacy data from a phase I/II trial presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
- 16 Feb 2017 CureVAc terminates a phase IIb clinical trial in Prostate cancer (Hormone refractory, Metastatic disease) as stated that follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome in Poland, France, United Kingdom, Switzerland, Sweden, Spain, Germany and Czech Republic (Intradermal) (NCT01817738)